Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT2527 in relapsed/refractory hematologic malignancies
NCT05665530Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- Sep 2023
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 1, open-label trial of PRT2527 in B-cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 9 more (4 arms), sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicity at 35 days, Adverse Events at 2 years and 2 more. Started Sep 2023; status: completed.
02
Drugs
PRT2527
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT05665530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665530.